JIPOAd
ESID
  • Users Online: 164
  • Print this page
  • Email this page


 Full text articles
CASE REPORT  
MET receptor amplification drives resistance to Anti-EGFR therapies
Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque, Ludovic Lacroix, Nathalie Auger, Eric Angevin, Lambros Tselikas, Sami Ammari, Jean-Charles Soria, Christophe Massard
[ABSTRACT]  [HTML FULL TEXT]  [PDF]
Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer
Yacine Wissam, Laila Belcaid, Ruth Wittoek, Vanessa Smith, Amber Vanhaecke, Sofie De Schepper, Lennart Jans, Daphné t'Kint de Roodenbeke, Andrea Gombos, Sandrine Aspeslagh
[ABSTRACT]  [HTML FULL TEXT]  [PDF]
EXPERT OPINION Top
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data
Katherine A Scilla, Alessandro Russo, Christian Rolfo
[ABSTRACT]  [HTML FULL TEXT]  [PDF]
ORIGINAL RESEARCH Top
Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: Data from the United States Food and Drug Administration adverse event reporting system
Xerxes N Pundole, Mayur Sarangdhar, Maria E Suarez-Almazor
[ABSTRACT]  [HTML FULL TEXT]  [PDF]
Safety of immune checkpoint blockade in patients with cancer and preexisting autoimmune diseases and/or chronic inflammatory disorders
Mohsin Shah, Mazen N Jizzini, Imad E Majzoub, Aiham Qdaisat, Cielito C Reyes-Gibby, Sai-Ching J Yeung
[ABSTRACT]  [HTML FULL TEXT]  [PDF]
REVIEW ARTICLE Top
Common cutaneous neoplasms in patients with immunodeficiency: A case series
Suhair Al Salihi, Haider A Mejbel, Victor G Prieto, Phyu P Aung
[ABSTRACT]  [HTML FULL TEXT]  [PDF]
Kaposi's sarcoma in the immunosuppressed
Nisha A Reddy, Steven R Mays, Omar Pacha
[ABSTRACT]  [HTML FULL TEXT]  [PDF]
Neuromuscular weakness syndromes from immune checkpoint inhibitors: A case series and literature review
Ahmad Daher, Carlos Kamiya Matsuoka, Monica Elena Loghin, Marta Penas-Prado, Sudhakar Tummala
[ABSTRACT]  [HTML FULL TEXT]  [PDF]


 Coming soon

INVITED EDITORIAL
1.  Cancer immunotherapy for the immunosuppressed: Dissecting the conundrum of safety and efficacy
REVIEW
1.  Immunocompromised Hosts and Cancer-HIV and Immunotherapy